FDA has granted GeneTek Xolair ® breakthrough therapy to identify foreheads to prevent food allergies

recently, Roche's GeneTek announced that the U.Sfda
(which has granted Xolair ® (omalizumab, Omazumab) breakthrough therapy to prevent accidental exposure to one or more foods can lead to severe allergic reactions in patientsbreakthrough therapy is based on seven clinical studies over the past 10 years that assess the effectiveness and safety of Xolair's effects on a range of food allergens, including peanuts, milk, eggs, and moreAs a single therapy or in combination with oral immunotherapy (OIT), the xolair study is supported by GeneTec and independent sponsors, including the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Healthin the United States, Genentech and NovartisPharmaceutical(co-developing and co-promoting Xolair)Genentech and Novartis are currently working closely with NIAID and the Food Allergy Research Consortium (CoFAR) on a potentially critical study to assess Xolair's effectiveness and safety in a variety of food allergies, and details will be revealed at a later dateabout Omaju mono-resistanceOmaju mono-resistance is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in blood and interstitial fluids and in the form of membrane binding (mIgE) of the surface of B lymphocytes that express mIgEIt binds to IgE to prevent IgE from binding to the FC-RI (high affinity IgE receptor) of alkaline granulocytes and hypertrophic cells, reducing the level of free IgE that can lead to an allergic cascade reactionWhen treating allergic body subjects, the Fc'ri receptor on alkaline cells can be significantly reducedOmaju monosantia was first approved in 2003 for the treatment of moderate to severe asthma, it is also the first biological agent to treat chronic isotype urticaria, and the firstdrug (
) approved for the treatment of chronic isotic urticaria, following non-sedative H1-antihistamineAs a prescription drug for subcutaneous injections, it has been approved for the treatment of patients with moderate to severe persistent asthma aged 6 years or older whose asthma symptoms are not controlled by asthma medications that inhale glucocorticoidsCheck through a skin or blood test to see if the patient is allergic to allergens throughout the year2) Chronic isotic urticaria patients 12 years and older who continue to develop urticaria without the control of H1 antihistamines (CIU; chronic urticaria for unknown reasons)the drug is not intended to treat other allergic diseases, other forms of urticaria, acute bronchospasm, or asthma